Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that ...

A 2009 study reported the design, construction and selection of a phage-encoded bicyclic peptide library that used a chemical linker for cyclization. This and other advanced display technologies ...

Bicycle Therapeutics has developed a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, and will gain funding for phase 1 and phase 1b clinical trial ...

Bicycle's bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data ...

Corero Network Security (AIM: CNS) , the distributed denial of service (DDoS) protection specialists, announced the successful onboarding of several new customers to its DDoS Protection-as-a-Service ...

The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology. It acts by targeting nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) by a ...

Bicycle Therapeutics (Nasdaq: BCYC), a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. The ...